Natco Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa®) from the United States Food and Drug Administration (U.S. FDA)".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has received a tentative approval from the U.S. FDA for its generic version of Balversa® (Erdafitinib Tablets), an oncology drug used to treat a type of bladder cancer. A tentative approval means the drug meets all FDA quality, safety, and efficacy standards but cannot be launched in the U.S. yet due to existing patents or exclusivity held by the brand owner. This positions Natco as one of the approved generic suppliers ready to enter the U.S. market once those restrictions are lifted. The U.S. FDA approval pathway is a key growth driver for Natco, which earns significant revenue from its U.S. generics business.
Positive for long-term prospects as it strengthens Natco's U.S. oncology pipeline, though immediate revenue impact is limited since launch awaits patent expiry or resolution. Investors may see this as a future earnings catalyst rather than a near-term trigger.